TRQ 1501
Alternative Names: Deep IL 15; Deep IL-15 primed T cells; TRQ-1501Latest Information Update: 02 Oct 2021
At a glance
- Originator Torque Therapeutics
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Lymphoma; Solid tumours
Most Recent Events
- 08 Nov 2019 Pharmacodynamics data from preclinical trial released by Torque Therapeutics
- 08 Nov 2019 Torque Therapeutics plans a clinical trial for TRQ 1501 in solid tumours and haematological malignancies (Combination therapy) in latter part of this year and in 2020
- 18 Jun 2019 Phase-I/II clinical trials in Lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (Torque Therapeutics pipeline, June 2019)